Investors

• PROGRESS IN DEVELOPMENT OF R&D PIPELINE
• SOLID CASH POSITION

Milan, Italy– March 27, 2007 - Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announces its financial results for the year ended 31 December 2007.

Highlights

• Ralfinamide in clinical development for the treatment of neuropathic
and inflammatory pain:
   • Commercial settlement with Purdue – option on Purdue patents
   • Positive phase II data in neuropathic pain
• Safinamide (cooperation with Merck Serono) in phase III clinical trials
for the treatment of patients with Parkinson’s disease (PD):
   • Long-term safety and efficacy data in PD
   • Extension of patent protection: EPO intention-to-grant letter received
     post end of reporting period
• Pre-clinical IND-enabling studies of NW-3509 initiated
• Opening of clinical development facility in Basel
• Lower net loss and solid cash position

In addition, in February 2008 Newron announced its intention to acquire Hunter-Fleming Ltd., a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders.

Luca Benatti, Newron’s CEO, commented: “2007 was a year of excellent progress in our development programs. The achievements with safinamide in Parkinson’s disease and ralfinamide in neuropathic pain further increase the value of these two important assets. In addition, the recently announced acquisition of Hunter-Fleming will further expand Newron’s pipeline. The company’s fundamentals are stronger than ever and we look forward to the upcoming significant milestones in 2008.”